FDA Clearance Tracker · P030031-S011
NAVISTAR & CELSIUS THERMOCOOL CATHETERS
Last checked: Nov 20, 2026Latest source record: Feb 6, 2009 (this decision)Source: openFDAMethods & limitations
Decided
Feb 6, 2009
Approved
Time to decision
177 days
Received Aug 13, 2008. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P030031-S011
- Device name
- NAVISTAR & CELSIUS THERMOCOOL CATHETERS
- Applicant
- Biosense Webster, Inc.
- Applicant location
- Irvine, CA
- Received
- Aug 13, 2008
- Decided
- Feb 6, 2009
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Original approval
- P030031
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE NAVISTAR THERMOCOOL CATHETER AND EZ STEER THERMOCOOL CATHETER-NAV VERSION. THESEDEVICES ARE INDICATED FOR CATHETER-BASED CARDIAC ELECTROPHYSIOLOGICAL MAPPING (STIMULATING ANDRECORDING), AND WHEN USED WITH THE STOCKERT 70 GENERATOR, FOR THE TREATMENT OF:1) TYPE I ATRIAL FLUTTER IN PATIENTS AGE 18 OR OLDER.2) RECURRENT DRUG/DEVICE REFRACTORY SUSTAINED MONOMORPHIC VENTRICULAR TACHYCARDIA(VT) DUE TO PRIOR MYOCARDIAL INFARCTION (MI) IN ADULTS.3) DRUG REFRACTORY RECURRENT SYMPTOMATIC PAROXYSMAL ATRIAL FIBRILLATION, WHEN USED WITH COMPATIBLE THREE-DIMENSIONAL ELECTROANATOMIC MAPPING SYSTEMS.
Source documents
Other decisions for Biosense Webster, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Dual Energy THERMOCOOL SMARTTOUCH SF SystemPMA supplement
P030031-S141 · Decided Jul 1, 2026 · 279 days after receipt · Panel Track
Device type: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter (OAD) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.